Comparison analysis of decitabine combined with CAG chemotherapy regimen in treating elderly acute myeloid leukemia
-
摘要: 目的:对地西他滨联合CAG方案治疗老年急性髓系白血病(AML)与单用CAG方案化疗的有效性和安全性进行比较。方法:选取76例老年AML患者,将其中46例采用地西他滨联合CAG方案治疗者设为观察组,其余30例单独行CAG方案治疗者设为对照组。治疗2个疗程后,比较2组的临床疗效及不良反应发生情况。结果:2种方案治疗老年AML均有一定疗效。观察组的完全缓解率及总有效率均明显高于对照组(均P<0.05)。观察组中MDS相关老年AML者的完全缓解率及总有效率均显著高于非MDS相关者(均P<0.05)。观察组化疗期间的不良反应发生情况与对照组比较,肺部感染、胃肠道反应、发热均明显增加,而血小板减少的发生率明显减少(均 P<0.05)。观察组中肺部感染率与年龄呈正相关(r=0.906,P=0.013)。结论:地西他滨联合CAG方案治疗老年AML疗效较好,尤其是对于MDS相关的老年AML,但同时肺部感染、恶心、呕吐等药物不良反应明显增加,部分老年人不能耐受,尤其是高龄患者需慎重使用。
-
关键词:
- 白血病,髓系,急性,老年 /
- 地西他滨 /
- CAG方案
Abstract: Objective:To investigate the curative effect and safety of decitabine combined with CAG regimen treatment for elderly acute myeloid leukemia (AML) patients.Method:A total of 76 elderly patients with AML were divided into observation group in which 46 patients received decitabine combined with CAG chemotherapy regimens and control group in which 30 patients received routine CAG chemotherapy treatment.The efficacy and adverse reactions were compared after two courses of chemotherapy.Result:Both two groups had certain curative effect in the treatment of elderly AML.The complete remission and total effective rates of the observation group were significantly higher than those of control group (P<0.05).The complete remission and total effective rates of AML related with MDS in the observation group were higher than those of AML not related with MDS (P<0.05).The incidences of adverse reactions such as pulmonary infection,gastrointestinal tract reaction and fever in observation group were significantly higher than those in control group during the chemotherapy,while the incidence of thrombocytopenia was lower than that in control group (P<0.05).In observation group,lung infection rate was positively correlated with age (r=0.906,P=0.013).Conclusion:Decitabine combined with CAG chemotherapy regimens has a good curative effect on the elderly AML,especially those associate with MDS.At the same time,incidences of pulmonary infection,nausea and vomiting increase obviously.Some patients can not tolerated,especially in aged patients.So we should be careful when use this regimen.-
Key words:
- elderly acute myeloid leukemia /
- decitabine /
- CAG regimen
-
-
[1] 林文远,莫东华,陈蓓莉,等.不同治疗方案对老年急性髓系白血病预后的影响[J].重庆医学,2010,39(5):577-579.
[2] 马泳泳,周淑娟,陈枫煜,等.地西他滨联合丙戊酸钠诱导的骨髓瘤细胞凋亡及其机制研究[J].解放军医学杂志,2013,38(10):837-841.
[3] 吕海容,邓琦,李玉明.地西他滨联合全反式维甲酸对HL-60细胞增殖及分化的影响[J].天津医药,2013,41(2):154-157.
[4] Pievani A,Borleri G,Pende D,et al.Dual-functional capability of CD3+CD56+ CIK cells,a T-cell subset that acquires NK functionand retains TCR-mediated specific cytotoxicity[J].Blood,2011,118:3301-3310.
[5] 张之南,沈悌.血液病诊断及疗效标准[M].3版.北京:科学出版社,2007:106-106.
[6] 谢兆霞,贺石林.老年血液病的诊断与治疗[M].长沙:中南大学出版社,2007:95-95.
[7] 阮长耿,昊德沛,李健勇,等.现代血液病诊断治疗学[M].合肥:安徽科学技术出版社,2007:335-335.
[8] 郝杰,程澍,王艳煜,等.地西他滨联合预激方案和传统治疗方案治疗老年MDS/MPD转化的急性髓系白血病的疗效和安全性的比较研究[J].临床血液学杂志,2014,27(1):15-18.
[9] Kantarjian HM,Thomas XG,Dmoszynska A,et al.Multicenter,randomized,open-label,phase III trial of decitabine versus patient choice,with physician advice,of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia[J].J Clin Oncol,2012,30:2670-2677.
[10] 刘真真,何广胜,吴德沛,等.减低剂量的地西他滨治疗骨髓增生异常综合征-难治性血小板减少[J].临床血液学杂志,2013,26(2):165-167.
[11] Oki Y,Kantarjian HM,Gharibyan V,et al.Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia[J].Cancer,2007,109:899-906.
-
计量
- 文章访问数: 340
- PDF下载数: 227
- 施引文献: 0
下载: